Dr. Robert Berryman, M.D.
What this data tells you about Dr. Berryman
Dr. Robert Berryman is a medical oncology in Dallas, TX, with 19 years in practice. Based on federal Medicare data, Dr. Berryman performed 104,583 Medicare services across 2,896 unique beneficiaries.
Between the years covered by Open Payments, Dr. Berryman received a total of $162,583 from 49 pharmaceutical and/or device companies across 330 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Berryman is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Immune globulin infusion (Octagam) | 31,800 | $33 | $234 |
| Filgrastim injection (Nivestym) for white blood cells | 27,102 | $0 | $2 |
| Injection, daratumumab, 10 mg | 23,240 | $46 | $167 |
| Dexamethasone injection (steroid) | 3,878 | $0 | $1 |
| Comprehensive metabolic blood panel | 1,812 | $10 | $64 |
| Measurement of immunoglobulin light chains | 1,801 | $17 | $60 |
| Lactate dehydrogenase (enzyme) level | 1,772 | $6 | $31 |
| Magnesium level test | 1,752 | $7 | $29 |
| Complete blood count (CBC) with differential | 1,477 | $8 | $36 |
| Blood draw (venipuncture) | 1,132 | $8 | $20 |
| Office visit, established patient (30-39 min) | 992 | $94 | $368 |
| Injection, granisetron hydrochloride, 100 mcg | 800 | $0 | $24 |
| Injection of additional new drug or substance into vein | 619 | $12 | $108 |
| Hospital follow-up visit, high complexity | 619 | $93 | $357 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 523 | $16 | $100 |
| Flow cytometry, additional marker | 502 | $19 | $180 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 449 | $22 | $157 |
| Injection, diphenhydramine hcl, up to 50 mg | 409 | $1 | $7 |
| Administration of chemotherapy into vein, 1 hour or less | 393 | $101 | $707 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 378 | $50 | $313 |
| Microscopic examination for white blood cells with manual cell count | 348 | $4 | $22 |
| Complete blood count (CBC), automated | 346 | $6 | $34 |
| Gammaglobulin (immune system protein) measurement, immunoglobulin subclasses | 340 | $8 | $236 |
| Drug injection, under skin or into muscle | 277 | $11 | $96 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 208 | $3 | $14 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 181 | $58 | $211 |
| Infusion, normal saline solution , 1000 cc | 111 | $2 | $19 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 109 | $89 | $657 |
| Tacrolimus level | 105 | $13 | $101 |
| Immunoglobulin level test | 99 | $9 | $56 |
| Injection, zoledronic acid, 1 mg | 92 | $7 | $431 |
| Nuclear medicine study whole body with ct scan | 79 | $1,180 | $4,929 |
| Infusion into a vein for hydration, each additional hour | 77 | $10 | $75 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 76 | $69 | $70 |
| Administration of vaccine, each additional vaccine | 60 | $12 | $58 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 57 | $14 | $94 |
| Administration of chemotherapy into vein, each additional hour | 56 | $21 | $161 |
| Ferritin level test (iron stores) | 42 | $13 | $60 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 37 | $1 | $19 |
| Infusion into a vein for hydration, 31-60 minutes | 32 | $26 | $256 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 30 | $1,142 | $4,802 |
| PSA test (prostate cancer screening) | 28 | $18 | $94 |
| Pneumococcal vaccine, 13-valent | 27 | $253 | $570 |
| Hepatitis b vaccine, adult dosage (3 dose schedule) | 27 | $69 | $165 |
| Unclassified drugs | 27 | $16 | $53 |
| Administration of vaccine | 25 | $16 | $58 |
| Initial hospital admission, high complexity | 25 | $130 | $694 |
| Flu vaccine administration | 23 | $31 | $58 |
| Pneumonia vaccine administration | 23 | $31 | $58 |
| Administration of hepatitis b vaccine | 23 | $31 | $58 |
| Flow cytometry technique for dna or cell analysis, first marker | 20 | $60 | $298 |
| Injection of drug or substance into vein | 20 | $30 | $247 |
| Office visit, established patient, complex (40-54 min) | 19 | $129 | $496 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 18 | $140 | $523 |
| Iron level test | 18 | $6 | $27 |
| Iron binding capacity test | 17 | $8 | $35 |
| Flu vaccine, quadrivalent | 16 | $76 | $171 |
| Hospital discharge management, 30+ min | 15 | $90 | $368 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (92%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 9% for medical oncology in TX.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Berryman is a mixed practice specialist, with above-average Medicare volume (top 10% in TX), and high industry engagement (speaking/promotional, top 9%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Berryman experienced with immune globulin infusion (octagam)?
Does Dr. Berryman receive payments from pharmaceutical companies?
How do Dr. Berryman's costs compare to other medical oncologys in Dallas?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology